Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

biotech dinosaurs cover2 1

In Depth 23 Jan 2018

Walking with the Dinosaurs of European Biotech: Which of Them is Roaring the Loudest?

Although biotech may seem like an industry that has only just gotten started, it was already up and running before the turn of the century. We took a look back at the pre-2000 companies to see how they’re faring. According to our biotech map, there were 219 biotechs in Europe in 1999. Today, our map […]

January 23, 2018 - 10 minutesmins - By Alex Dale

crispr gene editing rules 1

News and Trends 22 Jan 2018

European Court Supports the Softening of CRISPR Gene Editing Rules

The tough regulations that apply to genetically modified organisms may no longer affect plants and animals created using CRISPR gene editing technology. The European Court of Justice has ruled that crops and drugs developed using precise gene-editing techniques like CRISPR/Cas9 may not need to be regulated as strictly as genetically modified organisms (GMOs). So far, […]

January 22, 2018 - 3 minutesmins - By Alex Dale

colorectal cancer pierre fabre2 1

News and Trends 22 Jan 2018

New Triple Combination Therapy Boosts Colorectal Cancer Survival

Pierre Fabre and Array BioPharma’s combination therapy for colorectal cancer has improved progression-free survival in a Phase III trial. French pharma Pierre Fabre and American biopharma Array BioPharma, has carried out an initial safety lead-in study for a Phase 3 trial evaluating a triple combination therapy for the treatment of metastatic colorectal cancer patients. The therapy was […]

January 22, 2018 - 3 minutesmins - By Alex Dale

pharmamar stock ovarian cancer

News and Trends 22 Jan 2018

PharmaMar Stock Crashes After Failed Ovarian Cancer Study

PharmaMar’s cancer drug Zepsyre has failed to prove more effective than chemo to treat ovarian cancer in Phase III, leading to a big hit to its stock. Based in Madrid, PharmaMar develops cancer drugs derived from marine organisms. Unfortunately, one of these compounds, lurbinectedin (Zepsyre), has failed to show better efficacy in treating ovarian cancer than chemotherapy in […]

January 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

leukemia drug genmab novartis 1

News and Trends 22 Jan 2018

Novartis Takes Genmab’s Leukemia Drug Off the Market

Genmab’s leukemia drug will be available around the world through compassionate use programs, while it will continue to be marketed as normal in the US. Blockbuster drug owner Genmab developed Arzerra for the treatment of chronic lymphocytic leukemia (CLL) but the drug will be taken off the market outside the US due to its low uptake. Novartis markets the drug and […]

January 22, 2018 - 3 minutesmins - By Alex Dale

Abcam Roche Antibodies

News and Trends 22 Jan 2018

Abcam Will Start Selling Over 700 Antibodies from Roche

Abcam and Roche have entered an agreement that will let Abcam sell 760 new antibodies to researchers worldwide through its online platform. Inspired by Amazon, Abcam has become one of Europe’s biggest biotechs by building a platform to make it easier for researchers to order the antibodies they need for their experiments. A new deal with […]

January 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

mosquito biting gene1 1

News and Trends 22 Jan 2018

No More Mosquito Bites? Targeting These Genes Could Prevent Future Outbreaks!

Researchers may have found a way to stop the female mosquitoes from biting you, which could help to prevent the spread of diseases like malaria. Scientists at the University of Birmingham in the UK and the University of Notre Dame in Paris, along with collaborators in the US, have identified 902 genes specific to blood-feeding mosquitoes […]

January 22, 2018 - 3 minutesmins - By Alex Dale

tigenix eduardo bravo interview

Interview 22 Jan 2018

Bravo! An Interview with the CEO of Takeda’s Recent Cell Therapy Target

I sat down with Eduardo Bravo, CEO of TiGenix, to talk about the technology that made his company so attractive to the pharma giant. After beginning his career in big pharma, Eduardo Bravo took the plunge into biotech in 2005 when he saw the opportunity for a breakthrough therapy at a small Spanish biotech called […]

January 22, 2018 - 6 minutesmins - By Evelyn Warner

origin of life bioluminescence protocell

More News! 20 Jan 2018

These Artists Recreate the Origins of Life with Bioluminescence

Evelina Domnitch and Dmitry Gelfand explore the origin of life by creating protocell bioluminescence that evokes the early forms of life on Earth. The origin of life is still a bit of a mystery. Scientists have narrowed it down to a series of processes that must have occurred billions of years ago for life to […]

January 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

crispr patents revoked ers genomics2 1

News and Trends 19 Jan 2018

The European Patent Office Revokes the Broad Institute‘s CRISPR Patents

The Broad Institute has been dealt a big blow in its battle for CRISPR/Cas9 intellectual property, with the European Patent Office revoking one of its patents. CRISPR/Cas9 has been hailed as the ‘scientific discovery of the century’ due to its capacity to modify the genome for the treatment of genetic diseases. The Broad Institute, set up by MIT […]

January 19, 2018 - 3 minutesmins - By Alex Dale

txcell car treg organ transplantation

News and Trends 18 Jan 2018

France Gets Ready to Test CAR-Treg Cells to Avoid Transplant Rejection

TxCell has received a €1.2 loan from Bpifrance to complete preclinical trials with its CAR-Treg technology for transplant rejection and start human testing. French biotech TxCell is finalizing the preparations to take its first cell therapy to clinical trials. The treatment, called HLA-A2 CAR-Treg, is intended for the prevention of chronic rejection after organ transplantation. […]

January 18, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

rebelbio cohort 5 launch 1

News and Trends 18 Jan 2018

Meet the 10 Promising Synbio Startups in RebelBio’s London Cohort

Irish accelerator RebelBio has launched its latest cohort of startups that will receive its support during a 3-month program at Imperial College London. RebelBio is a startup accelerator that helps entrepreneurs to build technology associated with the life sciences field. It offers seed funding, lab space, mentorship, and a community of successful and diverse founders […]

January 18, 2018 - 4 minutesmins - By Alex Dale

ADVERTISEMENT